TRU-SENTIMENT ยท DeltaNeutral
OCGN Trading Analysis - 11/05/2026 11:29 AM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
OCGN (Ocugen Inc. Common Stock) at $0.82. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $720 vs put $0. RSI 54.7.
- Symbol
- OCGN
- Price
- $0.82
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-05 11:29:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From the embedded True Sentiment options data:
Call Volume: $720.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $720.00
- Sentiment is Bullish with 24 call contracts vs 0 put contracts, 3 call trades, 0 put trades.
- Pure directional conviction (Delta 40-60 filter) shows 100% call dollar volume, but only 3 of 88 total options met the filter (3.4%).
- Near-term expectations lean bullish per options flow, yet the spread recommender notes divergence: technicals show no clear direction.
- Notable divergence: bullish sentiment vs MACD negative and price below SMA 50.
Key Statistics: OCGN
Fundamental Snapshot
Valuation
| P/E (trailing) | 2.30 |
| EPS (trailing 12 mo) | $-0.26 |
| Market cap | $276.00M |
| Shares outstanding | 339.1M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 2.31 |
| 52-week low | $0.69 |
| 52-week high | $2.73 |
| Historical volatility | 76.0% |
Ownership & trading
| Institutional ownership | 26.7% |
| Average daily volume | 7.2M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following items are based on general knowledge and are separated from the data-driven sections below.
- Ocugen (OCGN) continues to advance its COVID-19 booster and rare eye-disease pipeline; recent partner updates on international vaccine rollouts have kept speculative interest elevated.
- Company presented at a recent biotech investor conference, highlighting progress on itsModifier gene therapy programs, a typical catalyst for retail momentum.
- No confirmed near-term earnings date in this context, but historical December fiscal-year-end implies updated financials could arrive in early 2027.
- Biotech sector remains sensitive to FDA commentary and funding headlines, which may amplify OCGN's already high beta of 2.31.
- Context: Headlines skew constructive, which loosely matches the embedded bullish options sentiment, though technicals remain inconclusive.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data:
- Trailing P/E is listed at 2.30, but trailing EPS is negative at -0.26, indicating the P/E is not meaningful for profitability assessment.
- Forward P/E, PEG ratio, price-to-book, total revenue, revenue growth, profit margins, ROE, and debt-to-equity are all null/unavailable in the data.
- Market cap is $276.00M with shares outstanding of 339.11M and institutional ownership at 26.71%.
- Beta is 2.31 and historical volatility is 75.95%, reflecting an elevated-risk small-cap biotech profile.
- 52-week range is $0.69 to $2.73; current price near $0.85 sits in the lower third of that range.
- No analyst consensus or target price is provided (recommendation key and target mean price are null).
- Fundamentals show a loss-making micro-cap with no disclosed cash-flow or margin data, which diverges from the bullish options sentiment and neutral technicals.
Current Market Position
Current price from indicators is $0.85 (calculated 2026-11-05). Daily history shows 2026-11-04 close at $0.85 with a range of $0.78โ$0.89 on volume of 7,602,829. Minute bars for 2026-11-04 opened at $0.81 and closed near $0.82; by 2026-11-05 11:00 the last bar shows open $0.83, high $0.83, low $0.82, close $0.82. Intraday momentum faded from the 2026-11-04 spike as price drifted from $0.86 (10:40 bar) to $0.82 by 11:00.
Technical Analysis
Technical Indicators
Price is above SMA 5 ($0.75) and SMA 20 ($0.81) but below SMA 50 ($1.00), showing short-term recovery within a longer downtrend. RSI at 54.66 is neutral with slight upward bias. MACD (-0.07) is below signal (-0.06) with negative histogram (-0.01), indicating mild bearish momentum. Bollinger mid is $0.81 with price just above; bands span $0.65โ$0.96 (no squeeze signal). 30-day range high $1.12, low $0.69; current $0.85 is roughly 43% up from the low. ATR of $0.06 implies daily movement near 7% of price.
True Sentiment Analysis (Delta 40-60 Options)
From the embedded True Sentiment options data:
Call Volume: $720.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $720.00
- Sentiment is Bullish with 24 call contracts vs 0 put contracts, 3 call trades, 0 put trades.
- Pure directional conviction (Delta 40-60 filter) shows 100% call dollar volume, but only 3 of 88 total options met the filter (3.4%).
- Near-term expectations lean bullish per options flow, yet the spread recommender notes divergence: technicals show no clear direction.
- Notable divergence: bullish sentiment vs MACD negative and price below SMA 50.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.